Shots:

• Sanofi will leverage its previous development work for a SARS vaccine and utilize its recombinant DNA platform to accelerate the development of a vaccine candidate against coronavirus
• The SARS vaccine candidates that were developed by Protein Sciences (acquired by Sanofi in 2017) provides a head start in expediting a COVID-19 vaccine
• Additionally- in Dec’2019- Sanofi collaborates with BARDA to form state of the art facilities in the US for the sustainable production of an adjuvanted recombinant vaccine to be used in influenza pandemic and is based on the same platform that will be used for the COVID-19 program

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Livemint